Novartis AG - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Novartis AG - Product Pipeline Review - 2016', provides an overview of the Novartis AG's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Novartis AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Novartis AG - The report provides overview of Novartis AG including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Novartis AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Novartis AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Novartis AG's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Novartis AG - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Novartis AG's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Novartis AG Snapshot 8 Novartis AG Overview 8 Key Information 8 Key Facts 8 Novartis AG - Research and Development Overview 9 Key Therapeutic Areas 9 Novartis AG - Pipeline Review 28 Pipeline Products by Stage of Development 28 Pipeline Products - Monotherapy 29 Pipeline Products - Combination Treatment Modalities 30 Pipeline Products - Partnered Products 31 Pipeline Products - Out-Licensed Products 34 Novartis AG - Pipeline Products Glance 36 Novartis AG - Late Stage Pipeline Products 36 Novartis AG - Clinical Stage Pipeline Products 40 Novartis AG - Early Stage Pipeline Products 49 Novartis AG - Drug Profiles 52 ceritinib 52 dabrafenib mesylate + trametinib dimethyl sulfoxide 55 eltrombopag olamine 57 everolimus 60 serelaxin 66 trametinib dimethyl sulfoxide 69 zoledronic acid 72 imatinib mesylate 74 panobinostat 77 pazopanib hydrochloride 84 (glycopyrrolate + indacaterol maleate + mometasone fuorate) 89 (indacaterol maleate + mometasone furoate) 90 (sacubitril + valsartan) 92 alpelisib 95 bimagrumab 97 buparlisib hydrochloride 99 canakinumab 103 dabrafenib mesylate 106 fevipiprant 109 fingolimod hydrochloride 111 midostaurin 114 nilotinib 116 ofatumumab 120 osilodrostat phosphate 125 oxytocin 127 pasireotide 129 pasireotide ER 132 ranibizumab 134 ribociclib 138 secukinumab 141 siponimod 147 CDZ-173 149 clofazimine 150 CNP-520 151 (dectrekumab + VAK-694) 152 afuresertib hydrochloride 153 aldesleukin 156 BHQ-880 158 BVS-857 160 capmatinib 161 CFZ-533 164 cipargamin 166 CJM-112 167 dectrekumab 168 EGF-816 170 elgemtumab 171 EMA-401 173 FCR-001 175 GSK-2285921 177 HSC-835 179 iloperidone 180 infigratinib 182 KAF-156 183 KRP-203 184 LCL-161 186 LFX-453 188 LHW-090 189 ligelizumab 190 LJN-452 192 LMI-070 193 mavoglurant 194 MCS-110 196 octreotide acetate long acting 197 pradigastat sodium 199 ruxolitinib phosphate 200 selurampanel 205 sonidegib phosphate 206 tesidolumab 210 tisagenlecleucel-T 212 trametinib dimethyl sulfoxide + uprosertib 215 uprosertib 217 VAY-736 218 BZF-961 220 CGF-166 221 CSJ-137 223 CSJ-148 224 FGF-401 225 HDM-201 226 LAG-525 227 lapatinib ditosylate 228 MGB-453 232 PDR-001 233 PIM-447 234 RAF-265 235 sotrastaurin acetate 236 ABL-001 238 AV-380 239 Cellular Immunotherapy to Target c-Met for Oncology 240 Cellular Immunotherapy to Target CD22 for Acute Lymphoblastic Leukemia 241 Cellular Immunotherapy to Target EGFR for Glioblastoma 242 CGM-097 243 CLR-325 244 huCART19 245 IDH-305 246 IMP-701 247 LEQ-506 248 LGK-974 249 LML-134 250 LNA-043 251 LXH-254 252 LXS-196 253 MesoCART 254 NOV-10 255 NOV-11 256 NOV-7 257 NOV-8 258 NOV-9 259 octreotide acetate LAR 260 PBF-509 261 PCA-062 263 QCC-374 264 CART-123 265 Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma 266 Antibody to Inhibit PD-L1 for Oncology 267 AUSRM-057 268 BLZ-945 269 BQS-481 271 BVB-808 272 Cellular Immunotherapy Program for Oncology 273 Cellular Immunotherapy to Target GD2 for Neuroblastoma 274 CHZ-868 275 cosyntropin ER 276 ESK-1 277 GNFPf-5069 278 Kartogenin 279 KR-22809 280 LCZ-960 281 LGB-321 282 LKZ-145 283 LQN-725 284 Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases 285 NIBR-0213 286 NITD-349 287 NITD-916 288 NVPQBE-170 289 NVPTNKS-656 290 OXB-302 291 RP-6503 292 Small Molecule to Agonize GPR119 for Type 2 Diabetes 293 Small Molecule to Agonize GPR39 for Type 2 Diabetes 294 Small Molecule to Agonize Nurr1 for Multiple Sclerosis 295 Small Molecule to Inhibit LRRK2 for Parkinson's Disease 296 Small Molecule to Inhibit OX2R for Insomnia 297 Small Molecules to Antagonize VEGFR2 for Solid Tumors 298 Small Molecules to Inhibit Cytochrome bc1 Complex for Tuberculosis 299 Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes 300 Small Molecules to Inhibit Pan PI3K for Ovarian Cancer 301 Small Molecules to Inhibit Pan-RAF Kinase for Oncology 302 Small Molecules to Inhibit Renin for Hypertension 303 XOMA-089 304 ESBA-903 SR 305 LJH-685 306 Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology 307 Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD 308 Small Molecules for Tuberculosis 309 Small Molecules for Undisclosed Indication 310 Small Molecules to Antagonize NR2B for Depression 311 Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections 312 Small Molecules to Inhibit CFTR for Secretory Diarrhea 313 Small Molecules to Inhibit FPPS for Soft Tissue Cancer 314 Small Molecules to Inhibit PfATP4 for Malaria 315 Small Molecules to Inhibit PI4KIIIbeta for HCV 316 Novartis AG - Pipeline Analysis 317 Novartis AG - Pipeline Products by Target 317 Novartis AG - Pipeline Products by Route of Administration 330 Novartis AG - Pipeline Products by Molecule Type 331 Novartis AG - Pipeline Products by Mechanism of Action 332 Novartis AG - Recent Pipeline Updates 342 Novartis AG - Dormant Projects 436 Novartis AG - Discontinued Pipeline Products 443 Novartis AG - Discontinued Pipeline Products 443 Discontinued Pipeline Product Profiles 445 Novartis AG - Company Statement 457 Novartis AG - Locations And Subsidiaries 458 Head Office 458 Other Locations & Subsidiaries 458 Appendix 475 Methodology 475 Coverage 475 Secondary Research 475 Primary Research 475 Expert Panel Validation 475 Contact Us 475 Disclaimer 476
List of Tables
Novartis AG, Key Information 21 Novartis AG, Key Facts 21 Novartis AG - Pipeline by Indication, 2016 23 Novartis AG - Pipeline by Stage of Development, 2016 41 Novartis AG - Monotherapy Products in Pipeline, 2016 42 Novartis AG - Combination Treatment Modalities in Pipeline, 2016 43 Novartis AG - Partnered Products in Pipeline, 2016 44 Novartis AG - Partnered Products/ Combination Treatment Modalities, 2016 45 Novartis AG - Out-Licensed Products in Pipeline, 2016 47 Novartis AG - Out-Licensed Products/ Combination Treatment Modalities, 2016 48 Novartis AG - Pre-Registration, 2016 49 Novartis AG - Filing rejected/Withdrawn, 2016 50 Novartis AG - Phase III, 2016 51 Novartis AG - Phase II, 2016 53 Novartis AG - Phase I, 2016 57 Novartis AG - Phase 0, 2016 61 Novartis AG - Preclinical, 2016 62 Novartis AG - Discovery, 2016 64 Novartis AG - Pipeline by Target, 2016 330 Novartis AG - Pipeline by Route of Administration, 2016 343 Novartis AG - Pipeline by Molecule Type, 2016 344 Novartis AG - Pipeline Products by Mechanism of Action, 2016 345 Novartis AG - Recent Pipeline Updates, 2016 355 Novartis AG - Dormant Developmental Projects,2016 449 Novartis AG - Discontinued Pipeline Products, 2016 456 Novartis AG, Subsidiaries 471
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.